| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5104543 | Value in Health | 2017 | 9 Pages |
Abstract
HB is associated with high economic burden, primarily because of clotting factor costs. Nevertheless, prophylaxis treatment leads to clinical benefits and may reduce other nonfactor costs.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Christina X. PhD, Judith R. DrPH, Michael B. PhD,